Myovant Sciences Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q2, Myovant Sciences (NYSE:MYOV) posted sales of $77.90 million. Earnings were up 67.99%, but Myovant Sciences still reported an overall loss of $18.35 million.
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech’s Vaccine For Children
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For October 26, 2021
Companies Reporting Before The Bell
• Veoneer (NYSE:VNE) is likely to report quarterly loss at $0.83 per share on revenue of $408.69 million.
Notable Insider Buys Of The Past Week Include Designer Brands, MacroGenics And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs.
The week's most notable insider buys were at two biotechs, a chemicals company and a shoemaker.
Some insiders were making return trips to the buy window.
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi’s Pemphigus Trial Disappointment, Humanigen’s COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 8)
Myovant Sciences And Pfizer Announce FDA Acceptance Of Supplemental New Drug Application For MYFEMBREE For The Management Of Moderate To Severe Pain Associated With Endometriosis
Myovant Sciences (NYSE:MYOV) and Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix
SVB Leerink Initiates Coverage On Myovant Sciences with Market Perform Rating, Announces Price Target of $24
SVB Leerink analyst Roanna Ruiz initiates coverage on Myovant Sciences (NYSE:MYOV) with a Market Perform rating and announces Price Target of $24.